A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite the use of warfarin, major systemic embolism remains an important complication in patients with heart-valve replacement. Although the addition of antiplatelet agents has the potential to reduce this complication, their efficacy and safety when given in combination with warfarin are uncertain. METHODS: In a randomized, double-blind, placebo-controlled trial, we assessed the efficacy and safety of adding aspirin (100 mg per day) to warfarin treatment (target international normalized ratio, 3.0 to 4.5) in 370 patients with mechanical heart valves or with tissue valves plus atrial fibrillation or a history of thromboembolism. RESULTS: A total of 186 patients were randomly assigned to aspirin and 184 to placebo, and they were followed for up to 4 years (average, 2.5). Major systemic embolism or death from vascular causes occurred in 6 aspirin-treated patients (1.9 percent per year) and 24 placebo-treated patients (8.5 percent per year) (risk reduction with aspirin, 77 percent; 95 percent confidence interval, 44 to 91 percent; P < 0.001). Major systemic embolism, nonfatal intracranial hemorrhage, or death from hemorrhage or vascular causes occurred in 12 patients assigned to aspirin (3.9 percent per year) and 28 patients assigned to placebo (9.9 percent per year) (risk reduction, 61 per cent; 95 percent confidence interval, 24 to 80 percent; P = 0.005); major systemic embolism or death from any cause occurred in 13 patients (4.2 percent) and 33 patients (11.7 percent), respectively (risk reduction, 65 percent; 95 percent confidence interval, 33 to 82 percent; P < 0.001); and death from all causes occurred in 9 patients (2.8 percent) and 22 patients (7.4 percent), respectively (risk reduction, 63 percent; 95 percent confidence interval, 19 to 83 percent; P = 0.01). Bleeding occurred in 71 patients in the aspirin group (35.0 percent), as compared with 49 patients in the placebo group (22.0 percent) (increase in risk, 55 percent; 95 percent confidence interval, 8 to 124 percent; P = 0.02); major bleeding occurred in 24 and 19 patients, respectively (increase in risk, 27 percent; 95 percent confidence interval, -30 to 132 percent; P = 0.43). CONCLUSIONS: In patients with mechanical heart valves and high-risk patients with prosthetic tissue valves, the addition of aspirin to warfarin therapy reduced mortality, particularly mortality from vascular causes, together with major systemic embolism. Although there was some increase in bleeding, the risk of the combined treatment was more than offset by the considerable benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis
Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., Gent, M., Turpie, A. G. G., McLoughlin, D., Dodd, P., Thomas, M., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212303072704 · Cited by 728
Self-citationThe Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 638
Twelve-Year Comparison of a Bjork–Shiley Mechanical Heart Valve with Porcine Bioprostheses
Bloomfield, P., Wheatley, D. J., Prescott, R. J., & Miller, H. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102283240901 · Cited by 428
Trial of Different Intensities of Anticoagulation in Patients with Prosthetic Heart Valves
Saour, J. N., Sieck, J. O., Mamo, L. A. R., & Gallus, A. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220703 · Cited by 368
Pharmacologic Control of Thromboembolic Complications of Cardiac-Valve Replacement
Sullivan, J. M., Harken, D. E., & Gorlin, R. (1971) · New England Journal of Medicine · doi:10.1056/nejm197106242842501 · Cited by 351
Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release Aspirin
Clarke, R. J., Mayo, G., Price, P., & FitzGerald, G. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110173251605 · Cited by 346
Turpie, A. G. G., Hirsh, J., Gunstensen, J., Nelson, H., & Gent, M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92070-3 · Cited by 315
Self-citationChesebro, J. H., Fuster, V., Elveback, L. R., McGoon, D. C., Pluth, J. R., Puga, F. J., Wallace, R. B., Danielson, G. K., Orszulak, T. A., Piehler, J. M., et al. (1983) · The American Journal of Cardiology · doi:10.1016/0002-9149(83)90673-2 · Cited by 300
Prevention of arterial thromboembolism with acetylsalicylic acid
Dale, J., Myhre, E., Storstein, O., Stormorken, H., & Efskind, L. (1977) · American Heart Journal · doi:10.1016/s0002-8703(77)80351-7 · Cited by 186
Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
Altman, R., Boullon, F., Rouvier, J., Raca, R., la Fuente, L. D., & Favaloro, R. (1976) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)40105-0 · Cited by 172
Stein, P. D., & Kantrowitz, Á. (1989) · CHEST Journal · doi:10.1378/chest.95.2_supplement.107s · Cited by 78
The Cardiopulmonary Response to OKT3 in Orthotopic Cardiac Transplant Recipients
Stein, K. L., Ladowski, J. M., KORMOS, R. L., et al. (1989) · CHEST Journal · doi:10.1378/chest.95.4.817 · Cited by 17
Cited by
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,495
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Authors/Task Force Members, Vahanian, A., Baumgartner, H., Bax, J., Butchart, E., Dion, R., Filippatos, G., Flachskampf, F., Hall, R., Iung, B., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl428 · Cited by 3,593
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Metadata
- Authors
- Turpie, A., Gent, M., Laupacis, A., Latour, Y., Gunstensen, J., Basile, F., Klimek, M., & Hirsh, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1993-08-19
- Volume
- 329
- Issue
- 8
- Pages
- 524-529
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2338244864
- Cited by
- 547
- References
- 17
- FWCI
- 26.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.